Responses
Clinical/translational cancer immunotherapy
Original research
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.